Efficacy and side effects of radiation therapy in comparison with radiation therapy and temozolomide in the treatment of measurable canine malignant melanoma.
Prognosis for unresectable canine malignant melanoma (MM) is typically poor, and therapeutic approaches remain largely palliative. A bi-institutional trial was conducted to compare efficacy and safety of radiation therapy (RT) and RT with post-radiation temozolomide in dogs with chemotherapy-naïve, measurable MM. RT consisted of 5 × 6 Gy fractions over 2.5 weeks. Dogs whose owners wished to pursue chemotherapy received adjuvant oral temozolomide (60 mg m-2for 5 days every 28 days). Fifteen dogs were treated with RT only (Group 1) and 12 dogs subsequently received temozolomide (Group 2). Overall response rate was similar between Group 1 (86.7%) and Group 2 (81.1%). Median time to progression (TTP) was significantly longer in Group 2 (205 days) compared to Group 1 (110 days; p = 0.046). Survival time was not significantly different between groups. Both treatments were well tolerated. Post-radiation temozolomide has a good safety profile, and may improve TTP in MM when compared to coarse fractionated RT.
Centro Oncologico Veterinario, Sasso Marconi, Italy.
S
S
Cancedda
Division of Radiation Oncology, Vetsuisse-Faculty, University of Zurich, Zurich, Switzerland.
C
C
Rohrer Bley
Department of Comparative Biomedicine and Food Science, University of Padua, Legnaro, Italy.
L
L
Aresu
Department of Comparative Biomedicine and Food Science, University of Padua, Legnaro, Italy.
M
M
Dacasto
Centro Oncologico Veterinario, Sasso Marconi, Italy.
V F
VF
Leone
Centro Oncologico Veterinario, Sasso Marconi, Italy.
S
S
Pizzoni
Clinica Veterinaria San Siro, Milan, Italy.
M
M
Gracis
Centro Oncologico Veterinario, Sasso Marconi, Italy.
L
L
Marconato
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004283:Dog Diseases / Q000628:therapy*; D004285:Dogs; D008545:Melanoma / Q000628:therapy / Q000662:veterinary*; D011878:Radiotherapy / Q000662:veterinary*; D000077204:Temozolomide
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide
dog; malignant melanoma; radiation therapy; temozolomide